Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Personalized tumor vaccine yields promising results in pilot trial
The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into
The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into
Through the partnership agreement, Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe. Humira is a TNF-inhibitor aimed at treating multiple chronic inflammatory
The two companies will also partner on the development and commercialization of GA Depot. GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting
The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). Combining this novel therapeutic strategy with
New investors include Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, and Venrock Healthcare Partners. Current investors, including The
Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, for which Verastem is seeking full approval for the treatment of relapsed or refractory chronic
EpiDestiny is eligible to receive more than 400 million US dollars in upfront, development and sales milestone payments and will get royalties on net sales. EpiDestiny and Novo
The approval is for patients who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line
These lawsuits allege that the aforementioned companies infringe the '305 patent, which was issued on April 3rd and has been submitted for listing in the FDA's Orange Book.
Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical trials and to continue preparations for Phase 3 clinical